Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20743061 | 0.83 | JAK2 (0.45) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22059523 | 0.81 | GRIN2B (0.54) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30328633 | 0.74 | RORC (0.38) | SMN1; SMN2NPC1RAB9AGRIN2BFAAH | |
| SCHEMBL20743055 | 0.74 | MAP3K12 (0.44) | MEN1KMT2AUSP30MAP3K12 | |
| SCHEMBL16158890 | 0.73 | SMN1; SMN2 (0.58) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL19404912 | 0.73 | GRIN2B (0.58) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2621378 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL70761 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL2621382 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL70762 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253499-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | disclosed |
| US-11253499-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | disclosed |
| EP-3668854-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-12 | — | — | EP | disclosed |
| EP-3668854-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-12 | — | — | EP | disclosed |
| EP-3668854-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-20200170997-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200170997-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| CN-111225909-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019034702-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034702-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253499-B2 | Compounds | SDHA, SDHB, FDPS | JAK2 1858/4885JAK1 2582/4885SMN1; SMN2 3636/4885 |
| US-20200170997-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | JAK2 2943/4885JAK1 2904/4885SMN1; SMN2 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.